ZyVersa Therapeutics

(OTC) ZVSA

Current Price$0.19

Market Cap$1.53M

Since IPO (2022)-100%

5 YearN/A

1 Year-73%

1 Month+2%

ZyVersa Therapeutics Financials at a Glance

Market Cap

$1.53M

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.82B

EPS (TTM)

-$3.32

P/E Ratio

-0.06

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.19

Volume

4,101

Open

$0.19

Price

$0.19

Volume

4,101

Open

$0.19

Previous Close

$0.19

Daily Range

$0.17 - $0.19

52-Week Range

$0.11 - $1.67

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.19

Volume

4,101

Open

$0.19

Previous Close

$0.19

Daily Range

$0.17 - $0.19

52-Week Range

$0.11 - $1.67

Estimated Earnings Date

Aug 13, 2026

ZVSA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ZyVersa Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Stephen C. Glover

Website

www.zyversa.com

Headquarters

Weston, FL 33326, US

ZVSA Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-113%

Return on Capital

-15%

Return on Assets

-2%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.53M

Shares Outstanding

8.10M

Volume

4.10K

Avg. Volume

10.39K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$6.84M

EBITDA

-$25.29M

Operating Cash Flow

-$5.11M

Capital Expenditure

$0.00

Free Cash Flow

-$5.11M

Cash & ST Invst.

$101.78M

Total Debt

$0.00

ZyVersa Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.53M

N/A

Market Cap/Employee

$218.59K

N/A

Employees

N/A

Net Income

-$1.79B

-79361.1%

EBITDA

-$1.30M

+42.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$302.66M

+18680.9%

Total Debt

$1.20B

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.20B

N/A

Return on Assets

-2.45%

N/A

Return on Invested Capital

-15.13%

N/A

Free Cash Flow

-$799.12M

+54.9%

Operating Cash Flow

-$799.12M

+54.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SLXNSilexion Therapeutics Ltd.

SLXNSilexion Therapeutics Ltd.$2.73-5.86%

ENVBEnveric Biosciences, Inc.

ENVBEnveric Biosciences, Inc.$1.28-1.54%

HEPAHepion Pharmaceuticals, Inc.

HEPAHepion Pharmaceuticals, Inc.$0.06-25.00%

NIVFNewGenIvf Group Limited

NIVFNewGenIvf Group Limited$0.76-5.30%

XAGELongevity Health Holdings Inc.

XAGELongevity Health Holdings Inc.$0.29+0.00%

ONCOOnconetix, Inc.

ONCOOnconetix, Inc.$0.94-5.13%

WORXSCWorx Corp.

WORXSCWorx Corp.$1.11+4.72%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$185.00-0.04%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.99+0.04%

QSQuantumScape

QSQuantumScape$8.04+0.17%

CMCSAComcast

CMCSAComcast$22.43-0.01%

RKLBRocket Lab

RKLBRocket Lab$107.24-0.01%

RIGTransocean

RIGTransocean$5.31-0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.16+0.02%

Questions About ZVSA

What is the current price of ZyVersa Therapeutics?

ZyVersa Therapeutics is trading at $0.19 per share.

What is the 52-week range for ZyVersa Therapeutics?

Over the past 52 weeks, ZyVersa Therapeutics has traded between $0.11 and $1.67.

How much debt does ZyVersa Therapeutics have?

As of the most recent reporting period, ZyVersa Therapeutics reported total debt of $1.20M.

How much cash does ZyVersa Therapeutics have on hand?

ZyVersa Therapeutics reported $302.66K in cash and cash equivalents in its most recent financial results.

What is ZyVersa Therapeutics’s dividend yield?

ZyVersa Therapeutics does not currently have a dividend yield.

ZyVersa Therapeutics

ZyVersa Therapeutics Financials at a Glance

ZVSA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ZyVersa Therapeutics

ZVSA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ZyVersa Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ZVSA

What is the current price of ZyVersa Therapeutics?

What is the 52-week range for ZyVersa Therapeutics?

How much debt does ZyVersa Therapeutics have?

How much cash does ZyVersa Therapeutics have on hand?

What is ZyVersa Therapeutics’s dividend yield?

Premium Investing Services